10x Genomics, Inc. — Form 8-K Summary
Business context and reporting period
10x Genomics filed this Form 8-K on November 2, 2022, under Items 2.02 and 9.01 to announce financial results for the quarter ended September 30, 2022. The filing relates to the company’s genomics technology business, but the provided text does not include operating or financial details from the accompanying press release.
Financial and operating metrics
- Revenue, profit, cash flow, margins, debt, liquidity, and other metrics: The filing text does not provide clear values.
- The referenced Exhibit 99.1 press release, which presumably contains the quarterly results, is not included in the provided filing text.
Material changes versus the prior comparable period
The filing text does not provide a comparison with the prior-year or prior-quarter period.
Guidance, outlook, risks, and unusual items
The filing text does not provide guidance, outlook commentary, risk updates, contingencies, or unusual items. Item 2.02 states that the filing and attached press release are furnished, not filed, for purposes of Section 18 of the Exchange Act, and are not incorporated by reference into other filings unless expressly specified.
Investor verification points
- Review Exhibit 99.1 for quarterly revenue, operating loss or profit, cash flow, cash and investments, and balance-sheet details.
- Verify any management guidance or outlook included in the press release.
- Compare the September 30, 2022 results with the corresponding prior-year and preceding-quarter periods.
- Assess any changes in cash usage, liquidity, debt, stock-based compensation, and operating expenses.